SCHEMBL6478093

SCHEMBL6478093

OC[C@H](Cc1ccc(Oc2ccnc3ccccc23)cc1)N(Cc1ccccc1)C[C@@H](O)c1cccc(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 3/20 0.39
ADRB3 P13945 9/20 0.37
ADRB1 P08588 5/20 0.36
ADRB2 P07550 4/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KDR P35968 3/20 0.36
CTSV O60911 1/20 0.35
CTSL P07711 1/20 0.35
CTSS P25774 1/20 0.35
BRAF P15056 1/20 0.34
MAPK14 Q16539 1/20 0.34
TNNI3K Q59H18 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6478089 1.00 SLC2A1 (0.39) SLC2A1ADRB3ADRB1ADRB2ADRA1D
SCHEMBL7689081 0.91 SLC2A1 (0.37) SLC2A1ADRB3ADRB1ADRB2ADRA1D
SCHEMBL7689078 0.91 SLC2A1 (0.37) SLC2A1ADRB3ADRB1ADRB2ADRA1D
SCHEMBL7693501 0.90 ADRB3 (0.44) SLC2A1ADRB3ADRB1ADRB2ADRA1D
SCHEMBL7693505 0.90 ADRB3 (0.44) SLC2A1ADRB3ADRB1ADRB2ADRA1D
SCHEMBL7687817 0.89 ADRB3 (0.39) SLC2A1ADRB3ADRB1ADRB2ADRA1D
SCHEMBL7687814 0.89 ADRB3 (0.39) SLC2A1ADRB3ADRB1ADRB2ADRA1D
SCHEMBL7689867 0.88 PDGFRA (0.36) SLC2A1ADRB3ADRB1ADRB2ADRA1D
SCHEMBL7689864 0.88 PDGFRA (0.36) SLC2A1ADRB3ADRB1ADRB2ADRA1D
SCHEMBL7695688 0.88 ADRB3 (0.38) SLC2A1ADRB3ADRB1ADRB2ADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2005-02-24 US disclosed
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143034-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB1, ADRB2, ADRB3 SLC2A1 2925/4885ADRB3 3/4885ADRB1 1/4885
US-20050043358-A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists ADRB2, ADRB1, ADRB3 SLC2A1 3066/4885ADRB3 3/4885ADRB1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.